NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Thermo Fisher Scientific' stock, noting the firm's increased scale as a result of its purchase of Life Technologies, as well as improving end markets.

The investment bank lifted Thermo Fisher's shares to a Buy rating from a previous Neutral rating and increased the 12-month price target on its stock to $153 from $114.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.